The effects of new pricing and copayment schemes for pharmaceuticals in South Korea

Health Policy

Volumn 104, Issue 1, 2012, Pages 40-49

  Lee, Iyn Hyang ^a   Bloor, Karen ^b   Hewitt, Catherine ^b   Maynard, Alan ^b  

^a Ajou University   (South Korea)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Copayment; Drug expenditure; Drug pricing; Pharmaceutical policy; Time series analysis

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; ROSUVASTATIN;

ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG UTILIZATION; HUMAN; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE PRICING; RETROSPECTIVE STUDY; SOUTH KOREA; TIME SERIES ANALYSIS;

COST CONTROL; COST SHARING; DRUG AND NARCOTIC CONTROL; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; REGRESSION ANALYSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES;

EID: 83555172298     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2011.09.003     Document Type: Article

References (50)

1. NHIC, HIRA Statistical booklet on 30 year-history of Korean National Health Insurance 2007, National Health Insurance Corporation, Health Insurance Review & Assessment Service, Seoul.
2. Cho J.-G., Choi S.-H., Lee S.-Y., Yoon K.-J. Achievements and policy implication of the Separation of prescribing and dispensing drugs 2003, Korea Institute for Health and Social Affairs, Seoul, [in Korean].
3. Cho J.-G., Kim J.-Y., Jang S.-M., Bae E.-Y., Lee S.-Y., Yoon K.-J. Monitoring health care utilisation behaviour after the inception of the separation of prescribing and dispensing drugs 2002, Korea Institute for Health and Social Affairs, Seoul, [in Korean].
4. Kim J.-Y. The impact of the separation of prescription and dispensing on medical service utilisation. Health and Welfare Forum 2002 February 2002, 6-19. [in Korean].
5. Cho J.-G., Lee E.-K., Kim J.-Y., Jang S.-M., Bae E.-Y., Park H.-K., et al. Evaluation and policy implication of the Separation of prescribing and dispensing drugs 2001, Korea Institute for Health and Social Affairs, Seoul, [in Korean].
6. Jang S.-M., Lee E.-K., Kim Y., Han E.-A., Bae E.-Y., Kim J.-Y., et al. Pharmaceutical utilisation before and after the separation of prescribing and dispensing of drugs; focusing on changes in prescribing behaviour 2001, Korea Institute for Health and Social Affairs, Seoul, [in Korean].
7. Kim S.-O. Realities in expensive drug prescribing and its determinants. Health Insurance Forum 2005, 4:57-83. [in Korean].
8. Lee E.K., Malone D.C. Comparison of peptic-ulcer drug use and expenditures before and after the implementation of a government policy to separate prescribing and dispensing practices in South Korea. Clinical Therapeutics 2003, 25:578-592.
9. Ministry of Health & Welfare Pharmaceutical expenditure rationalisation plan 2006, Ministry of Health & Welfare, Gwacheon, [in Korean], http://www.mw.go.kr/front/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=1&BOARD_ID=140&BOARD_FLAG=&CONT_SEQ=37687.
10. Lee Y.-C., Yang M.-C., Huang Y.-T., Liu C.-H., Chen S.-B. Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003. Pharmacoeconomics 2006, 24:891-902.
11. Sawyer DO. Pharmaceutical reimbursement and drug cost control: the MAC experience in Maryland Inquiry 1983; 20:76-87.
12. Jacobzone S. Pharmaceutical policies in OECD countries: reconciling social and industrial goals 2000, Organisation for Economic Co-operation and Development, Paris.
13. Harris B.L., Stergachis A., Ried L.D. The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Medical Care 1990, 28:907-917.
14. Roblin D.W., Platt R., Goodman M.J., Hsu J., Nelson W.W., Smith D.H., et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much?. Medical Care 2005, 43:951-959.
15. Landon B.E., Rosenthal M.B., Normand S.-L.T., Spettell C., Lessler A., Underwood H.R., et al. Incentive formularies and changes in prescription drug spending. American Journal of Managed Care 2007, 13:360-369.
16. Soumerai S.B., Avorn J., Ross-Degnan D., Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity New England. Journal of Medicine 1987, 317:550-556.
17. Sun S.X., Lee K.Y. The Medicare Part D doughnut hole: effect on pharmacy utilization. Managed Care Interface 2007, 20:51-55.
18. Tamblyn R., Laprise R., Hanley J.A., Abrahamowicz M., Scott S., Mayo N., et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001, 285:421-429.
19. Soumerai S.B., Ross-Degnan D., Avorn J., McLaughlin Tj, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes New England. Journal of Medicine 1991, 325:1072-1077.
20. Franco O.H., Peeters A., Bonneux L., de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension 2005, 46:280-286.
21. Anderson K.M., Castelli W.P., Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham Study. JAMA 1987, 257:2176-2180.
22. Soumerai S.B., McLaughlin T.J., Ross-Degnan D., Casteris C.S., Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia New England. Journal of Medicine 1994, 331:650-655.
23. Kanavos P., Ross-Degnan D., Fortess E., Abelson J., Soumerai S. Measuring, monitoring and evaluating policy outcomes in the pharmaceutical sector 2004, Open University Press, Maidenhead.
24. Klein R. Learning from others: shall the last be the first?. Journal of Health Politics, Policy & Law 1997, 22:1267-1278.
25. Bae E.-Y., Kim J.-H. Pharmaceutical price regulation in Korea 2001, Korea Institute for Health and Social Affairs, Seoul, [in Korean].
26. Lee E.-K. Reimbursement pricing and some policy implications. Health Insurance Forum 2006, 5:2-14. [in Korean].
27. Ministry of Health & Welfare Implementing 30% coinsurance for outpatient medical services and prescription drugs 2007, Ministry of Health & Welfare, Gwacheon, [in Korean].
28. Health Insurance Review & Assessment Service WHO ATC classification for prescription medications 2007, Health Insurance Review & Assessment Service, Seoul, [in Korean].
29. Wagner A.K., Soumerai S.B., Zhang F., Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy & Therapeutics 2002, 27:299-309.
30. DailyPharm AstraZeneca launching superstatin 'Crestor' into the Korean market 2004, DailyPharm.
31. DailyPharm Plavix pull down Novasc out of the first place 2009, DailyPharm.
32. Durbin J., Watson G.S. Testing for serial correlation in least squares regression. I. Biometrika 1950, 37:409-428.
33. Durbin J., Watson G.S. Testing for serial correlation in least squares regression. II. Biometrika 1951, 38:159-178.
34. Ostrom C.W.J. Time series regression analysis: nonlagged case. Time series analysis: regression techniques 1990, 7-42. SAGE Publications, Inc., London. 2nd ed.
35. StataCorp LP. Stata/SE 10.0 for Windows Texas; 2007.
36. McCain L.J., McCleary R. The statistical analysis of the simple interrupted time-series quasi-experiment 1979, Houghton Mifflin Company, London.
37. McDowall D., McCleary R., Meidinger E.E., Hay R.A.J. Interrupted time series analysis 1980, SAGE Publications Ltd, London.
38. The R foundation for statistical computing. 2010.
39. Goldman D.P., Joyce G.F., Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007, 298:61-69.
40. Soumerai S.B., Ross-Degnan D., Fortess E.E., Abelson J. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. Milbank Quarterly 1993, 71:217-252.
41. Austvoll-Dahlgren A., Aaserud M., Vist G., Ramsay C., Oxman A.D., Sturm H., et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database of Systematic Reviews 2008, CD007017.
42. Federman A.D., Halm E.A., Zhu C., Hochman T., Siu A.L. Association of income and prescription drug coverage with generic medication use among older adults with hypertension American. Journal of Managed Care 2006, 12:611-618.
43. Huh S.-I., Jung J.-C., Lee H.-Y. A strategy for rationalising pharmaceutical expenditure 2006, National Health Insurance Corporation, Seoul, [in Korean].
44. Yoon H.-S. National Insurance reimbursement pricing scheme: challenges and a strategy for improvement 2008, Korea Development Institute, Seoul, [in Korean].
45. Lee T.-L., Hsuan C.-F., Chang H.-L., Wu G.H.-M., Tseng W.-K., Wu C.-C. Is it cost-effective to change brand-name to generic simvastatin in Taiwan?. Acta Cardiologica Sinica 2008, 24:191-197.
46. European Generic Medicines Association The use of generic medicines in Europe Brussels: European Generic Medicines Association 2007, http://www.egagenerics.com/gen-geneurope.htm.
47. Simoens S., De Coster S. Sustaining generic medicines markets in Europe: Research Centre for Pharmaceutical Care and Pharmaco-economics 2006, Katholieke Universiteit Leuven.
48. Shin J.-Y., Choi S.-E. The volume and the price of generic drug consumption in Korean prescription drug market. The Korean Journal of Health Economics and Policy 2008, 14:103-125. [in Korean].
49. Lim J.-K. Study on determinants of market share for generic drug in Korean market 2002, Chung-Ang University, Seoul, [in Korean], Master.
50. You M.-Y. A study on the market-share of original drugs since first generic entry 2007, Yonsei University, Seoul, [in Korean], Master.